Celyad Oncology SA CLYYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -95.53% | -95.66% | 5.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -95.53% | -95.66% | 5.33% |
| Cost of Revenue | -98.31% | -98.18% | -100.00% | -100.00% | 2,737.50% |
| Gross Profit | 98.21% | 98.07% | -95.45% | -95.59% | -4,848.15% |
| SG&A Expenses | -71.59% | -69.18% | 56.97% | 52.86% | -16.77% |
| Depreciation & Amortization | -78.41% | -76.51% | -- | -- | -- |
| Other Operating Expenses | -57.36% | -53.74% | -2,860.84% | -2,783.85% | 1,155.72% |
| Total Operating Expenses | -66.53% | -63.69% | -178.37% | -176.31% | 24.85% |
| Operating Income | 66.40% | 63.55% | 183.48% | 181.29% | -24.93% |
| Income Before Tax | 66.26% | 63.39% | 276.97% | 272.33% | -27.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 66.26% | 63.39% | 276.97% | 272.33% | -27.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.26% | 63.39% | 276.97% | 272.33% | -27.30% |
| EBIT | 66.40% | 63.55% | 183.48% | 181.29% | -24.93% |
| EBITDA | 65.69% | 62.78% | 186.42% | 188.31% | -27.42% |
| EPS Basic | 68.85% | 66.17% | 265.92% | 261.79% | -33.69% |
| Normalized Basic EPS | 68.89% | 66.10% | 177.23% | 175.32% | -34.04% |
| EPS Diluted | 68.85% | 66.17% | 243.30% | 239.84% | -33.69% |
| Normalized Diluted EPS | 68.89% | 66.10% | 166.52% | 164.94% | -34.04% |
| Average Basic Shares Outstanding | 8.12% | 8.05% | 6.52% | 6.52% | -4.80% |
| Average Diluted Shares Outstanding | 8.12% | 8.05% | 23.36% | 23.36% | -4.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |